Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Kurlemann, Gerhard
Bast, Thomas
Bettendorf, Ulrich
Kluger, Gerhard
Mayer, Thomas
Neubauer, Bernd A.
Polster, Tilman
von Spiczak, Sarah
Trollmann, Regina
Wolff, Markus
Toward, Toby
Gruenert, Jens
Gibson, Eddie
Pritchard, Clive
Carroll, Joe
Rosenow, Felix
Schubert-Bast, Susanne
Funding for this research was provided by:
Zogenix
Article History
Received: 10 April 2022
Accepted: 2 May 2022
First Online: 6 June 2022
Declarations
:
: The study had an ethics approval and was registered at the German Clinical Trials Register (DRKS00011894). STROBE guidelines were followed.
: Not applicable.
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharma, Precisis, UCB, UNEEG medical, and Zogenix.GKu reports personal fees from UCB Pharma, Desitin Arzneimittel, Zogenix, LivaNova, Eisai, GW Pharma, Bial, Dibropharma, Novartis, Biogen, Actelion.TB reports fees from Desitin Arzneimittel, GW Pharma, and Zogenix.GKl reports personal fees from Desitin Arzneimittel, Eisai, and Zogenix.RT reports personal fees and grants from Novartis, Desitin Arzneimittel, UCB Pharma and Pfizer.TT and JG are employed by Zogenix International Ltd.EG, CP, and JC were employed by Wickenstones Ltd. and received support from Zogenix International Limited to complete this study.FR reports personal fees from Eisai, UCB Pharma, Desitin Arzneimittel, Novartis, GW Pharma, Medtronic, Cerbomed and Shire, grants from the European Union, Deutsche Forschungsgemeinschaft, the federal state Hessen through the LOEWE programme, and the Detlev-Wrobel-Fonds for Epilepsy Research.SSB reports personal fees from UCB, Desitin Arzneimittel, Novartis, Zogenix, LivaNova, and Eisai.